RxDoctor Payments DataLook up a doctor →

Robert Seward, MD

Psychiatry · Richmond, VANPI 1063402600

Payments from drug & device makers

$14,435in general payments, 2019–2025

Across 900 payments — averaging $16.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Lundbeck LLC$1K
  • Johnson & Johnson$1K
  • Otsuka America Pharmaceutical, Inc.$1K
  • Takeda Pharmaceuticals U.S.A., Inc.$919
  • Neurocrine Biosciences, Inc.$874
  • plus $7K from 31 others

What the payments were for

  • Food & beverage$14,419100%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,435 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.

See all psychiatry providers in Virginia

Medicare billing

Part B allowed, 2024
$299,035
Medicare patients
463
Services billed
2,767

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole33$46,933
TrintellixVortioxetine Hydrobromide23$19,428
VraylarCariprazine Hcl22$15,985
Aripiprazole268$10,148
Venlafaxine Hcl ErVenlafaxine Hcl292$9,874
Lurasidone Hcl28$8,557
Quetiapine Fumarate521$8,398
Bupropion XlBupropion Hcl305$8,102
Buspirone Hcl565$7,726
Olanzapine251$7,156
Duloxetine Hcl317$6,341
Chlorpromazine Hcl14$6,293
Trazodone Hcl384$5,326
Sertraline Hcl610$4,724
Clonazepam653$4,540

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$1,082$46,93333 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$919$19,42823 claims
AbbVieVraylar$1,594$15,98522 claims
Almatica Pharma LLCSertraline Hcl$270$4,724610 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.

Other psychiatry in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →